glp-1 in heart failure receptor agonists and myocardial metabolism atrial fibrillation Mechanisms of GLP-1 Receptor Agonists

As we adopt this new technology, we are able to lead the way in patient care with excellent outcomes

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

Epidemiological studies have identified a significant association between kidney stone disease and NAFLD, suggesting they frequently co-exist in the same individuals

This approach allows your body to readjust and helps minimize side effects that sometimes feel more intense after a medication pause

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinsons disease

3,4 These metabolic comorbidities, such as obesity, insulin resistance, and cardiovascular disease, exacerbate disease severity and complicate management